NEWS
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
Oragenics Inc. (NYSE American: OGEN) has announced that its lead candidate for treating concussion, ONP-002, has successfully completed FDA-required cardiotoxicity testing. The drug showed no signs of causing cardiac arrhythmia, demonstrating a strong safety margin for the heart. This clearance allows Oragenics to proceed with planning Phase II clinical trials for concussion treatment.
ONP-002 is a new chemical entitydesigned for intranasal delivery to target the brain. The potential addressable market for ONP-002 is significant, with an estimated 69 million concussions reported annually worldwide. The total annual healthcare cost for nonfatal traumatic brain injuries in the US exceeds $40.6 billion, highlighting the substantial market opportunity for effective concussion treatments.
ONP-002 is a new chemical entitydesigned for intranasal delivery to target the brain. The potential addressable market for ONP-002 is significant, with an estimated 69 million concussions reported annually worldwide. The total annual healthcare cost for nonfatal traumatic brain injuries in the US exceeds $40.6 billion, highlighting the substantial market opportunity for effective concussion treatments.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1822Followers
98Following
15KVisitors
Follow